Summary
Most claims provided are about Medicare coverage and administration practices, which are not addressed in the supplied FDA label excerpts. The only clearly label-addressable safety-related content is not present in the AI claims, and therefore multiple claims are unsupported by the provided prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Cosentyx (secukinumab) is generally treated as a prescription drug covered under Medicare Part D (or a Medicare Advantage plan that includes Part D).
Not supported by the provided FDA label excerpts (which cover warnings/precautions and limited procedural counseling) and includes no information about Medicare Part D coverage.
Cosentyx is generally not covered as a typical Medicare Part B benefit.
Not supported by the provided FDA label excerpts; no Medicare Part B/Part D coverage information is present.
Cosentyx is a self-administered medication.
Not supported by the provided FDA label excerpts; no patient administration/self-injection instructions are included in the supplied text.
Cosentyx is often given by injection at home.
Not supported by the provided FDA label excerpts; no statements about at-home injection frequency or typical administration setting are included.
Medicare Part B usually covers only specific drug categories, such as drugs administered in a clinician’s office under Part B rules.
Not supported by the provided FDA label excerpts; Medicare coverage rules are not addressed.
Medicare Part B can apply to certain drugs when they are furnished in specific clinical settings or meet specific Part B coverage rules.
Not supported by the provided FDA label excerpts; Medicare coverage rules are not addressed.
Whether Cosentyx is covered under Part B depends on how it is billed and administered.
Not supported by the provided FDA label excerpts; no billing/administration-dependent Medicare coverage statements are included.
In most cases, patients get Cosentyx through Part D or through a Part D-included Medicare Advantage plan rather than Part B.
Not supported by the provided FDA label excerpts; no claims about 'most cases' or distribution of coverage sources are included.
Patients typically need to check the plan’s formulary (drug list) and cost-sharing under Medicare Part D or a Medicare Advantage plan that includes drug coverage.
Not supported by the provided FDA label excerpts; no formulary/cost-sharing guidance is included.
Contradictions
Important Omissions
No on-label statements are made regarding COSENTYX-specific safety warnings (e.g., infection risk, TB evaluation, hypersensitivity, IBD risk, immunizations) despite the provided label excerpts being warnings/precautions-focused.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The evaluated claims are primarily about Medicare coverage and administration setting; they are not supported by the provided label excerpts. As such, any patient-impact would stem from misinformation not corroborated by the supplied prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Needs Review
Primary Issue
Multiple claims are unsupported because the supplied FDA label excerpts do not include Medicare coverage information or administration/self-injection/at-home usage guidance.
Suggested Improvement
Limit claims to information present in the provided label excerpts (e.g., infections, TB evaluation, immunization guidance) and avoid Medicare coverage and administration-setting statements unless supported by relevant on-label sections not included in the provided text.